Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of fertility-sparing treatment with LNG-IUS is associated with different ProMisE subtypes of endometrial carcinoma or atypical endometrial hyperplasia.

Journal of gynecologic oncology - 1 May 2024

Lv Xiaofeng, Guo Lili, Wang Changyu

Abstract excerpt

OBJECTIVE: To determine whether proactive molecular risk classifier for endometrial cancer (ProMisE) could be used to assess the prognosis of patients with atypical endometrial hyperplasia (AEH) or early-stage endometrial cancer (EC) treated with levonorgestrel-releasing intrauterine system (LNG-IUS). METHODS: A retrospective cohort study was conducted among 93 AEH or early-stage EC patients who received LNG-IUS...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Endometrial Hyperplasia
Share to Endometrial Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Poly-ADP-Ribose Binding Proteins

Share to Treatment Outcome

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 38216133
DOI: 10.3802/jgo.2024.35.e27
PMCID: PMC11107283

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of fertility-sparing treatment with LNG-IUS is associated with different ProMisE subtypes of endometrial carcinoma or atypical endometrial hyperplasia.PMID 38216133Read ↗

Potential of molecular classification to guide fertility-sparing management among young patients with endometrial cancer.Semantic proximity Read ↗

Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer.Semantic proximity Read ↗

Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.Semantic proximity Read ↗

Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer.Semantic proximity Read ↗

PTEN mutation predicts unfavorable fertility preserving treatment outcome in the young patients with endometrioid endometrial cancer and atypical hyperplasia.Semantic proximity Read ↗

The TCGA Molecular Classification of Endometrial Cancer and Its Possible Impact on Adjuvant Treatment DecisionsSemantic proximity Read ↗

[Thoughts on the molecular characteristics of endometrial cancer in clinical diagnosis and treatment].Semantic proximity Read ↗

Analysis of patients with endometrial carcinoma using the ProMise classifier: a pilot study from India.Semantic proximity Read ↗

Associations between molecular subtypes and high-risk pathological factors in endometrial cancer.Semantic proximity Read ↗

Tailoring Endometrial Cancer Treatment Based on Molecular Pathology: Current Status and Possible Impacts on Systemic and Local Treatment.Semantic proximity Read ↗

New clinicopathological concept of endometrial carcinoma with integration of histological features and molecular profiles.Semantic proximity Read ↗

Analysis of fertility-preserving treatment outcomes in patients with POLE-mutated endometrioid carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.